Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look into strategic alternatives for the company.

Last year, EMD Serono took a big step by moving its U.S. headquarters to Boston’s Seaport neighborhood. EMD Serono is the North American drug development business of Merck KGaA, Darmstadt ...

The German manufacturer has been exiting heavy-equipment businesses and shifting its focus to software to improve ...

GE HealthCare (Nasdaq: GEHC) announced today that it appointed Jeannette Bankes as president and CEO for its Patient Care ...

The judge’s decision came as the Trump administration has moved to end legal protections for migrants from many countries, ...

Dr. Roger Dansey Dr. Roger Dansey joins Ottimo Pharma Limited Board of Directors Dansey, a former senior executive at Pfizer ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

The owners of what was once Pennsylvania’s biggest coal-fired power plant said Wednesday that they will turn it into a $10 ...

German industrial giant Siemens AG said today it will pay $5.1 billion to acquire the life sciences data startup Dotmatics in ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025.